Richemont Says It Has No Plans to Invest in Farfetch, or Lend to It
By Andrea Figueras
Compagnie Financiere Richemont said that it has no financial obligations toward the luxury fashion e-commerce company Farfetch and doesn't plan to lend to or invest in it.
The Swiss-based luxury group's release comes after Farfetch said late Tuesday that it wouldn't publish its third-quarter results, which were due Wednesday. The company won't provide forecasts at this time, and any prior guidance should no longer be relied upon, Farfetch said.
Earlier Tuesday, UK newspaper Telegraph reported that Jose Neves, founder of the online luxury retailer, was in talks with top shareholders to take the company private. According to the newspaper, the move could have the tentative backing of major backers including Chinese e-commerce giant Alibaba and Richemont.
Farfetch declined to comment.
Richemont said that it is monitoring the situation, including reviewing its options in respect of its arrangements with Farfetch, which remain subject to certain terms and conditions, including the sale of a stake in online platform Yoox Net-A-Porter to the luxury fashion e-commerce company.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
November 29, 2023 02:18 ET (07:18 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks